Oct 18 (Reuters) – NuCana PLC: * NUCANA PRESENTS ENCOURAGING DATA ON NUC-7738 IN COMBINATION WITH PD-1 INHIBITORS USING PRIMARY PATIENT-DERIVED ORGANOIDS AND AUTOLOGOUS TUMOR-INFILTRATING LYMPHOCYTES AT THE ESMO CONGRESS 2025 * NUCANA PLC – REGULATORS APPROVE STUDY EXPANSION FOR 28 MORE PATIENTS * NUCANA PLC – DATA TO DATE FROM NUTIDE:701 SHOWS FAVORABLE SAFETY AND TUMOR REDUCTION Source text: Further company coverage:
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Jan 12 (Reuters) - Alphabet hit a $4 trillion market valuation on Monday, as the…
Jan 12 (Reuters) - Governments and regulators from Europe to Asia are cracking down on…
Budapest (dpa) - Anyone who has kept different dogs as pets will have noticed over…
Fresh, crunchy and, yes, tasty: New ways to prepare Brussels sprouts could persuade even firm doubters…
WASHINGTON, Jan 12 (Reuters) - U.S. President Donald Trump will interview BlackRock Inc's chief bond…
With global quant funds experiencing significant growth and India commanding a substantial share of global…